[The inhibitory effect of recombinant fibronectin polypeptide CH50 on the growth of B16 melanoma]

Zhonghua Zhong Liu Za Zhi. 1999 Nov;21(6):416-8.
[Article in Chinese]

Abstract

Objective: To study the inhibitory effect of CH50, a recombinant polypeptide consisting of 2 binding domains of human fibronectin, on the growth of B16/F1 melanoma in mice.

Methods: Mice inoculated with B16/F1 cells were treated with CH50. The growth inhibitory effect on i.p. inoculated tumor was assessed by the number and size of tumor nodules in the peritoneal cavity, and on s.c. inoculated tumor by tumor size.

Results: For s.c. inoculated B16/F1, CH50 injected at the tumor site led to 50% inhibition of tumor growth while injection at a distant site was much less effective. In mice bearing i.p. inoculated tumor, the growth inhibition by CH50 on tumor nodules < 1 mm in diameter was 80% and 50+% on those > 1 mm. Synergistic therapeutic effect was obtained when CH50 used in combination with hydroxycamptothecine (HCPT).

Conclusion: CH50 is effective in the treatment of B16/F1 melanoma. The effect can be enhanced when used in combination with HCPT.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Camptothecin / therapeutic use
  • Dose-Response Relationship, Drug
  • Fibronectins / therapeutic use*
  • Melanoma, Experimental / drug therapy*
  • Melanoma, Experimental / pathology
  • Mice
  • Mice, Inbred C57BL
  • Recombinant Proteins / therapeutic use

Substances

  • Antineoplastic Agents
  • Fibronectins
  • Recombinant Proteins
  • Camptothecin